Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients

Journal of Nuclear Medicine

Volumn 47, Issue 10, 2006, Pages 1565-1570

  Ypenburg, Claudia ^a   Schalij, Martin J ^a   Bleeker, Gabe B ^a,b   Steendijk, Paul ^a   Boersma, Eric ^c   Dibbets Schneider, Petra ^a   Stokkel, Marcel P ^a   Van Der Wall, Ernst E ^a   Bax, Jeroen J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

18F FDG SPECT; Cardiac resynchronization therapy; Heart failure

Indexed keywords

ACIPIMOX; FLUORODEOXYGLUCOSE F 18; NICOTINIC ACID DERIVATIVE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QRS COMPLEX; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; HEART; HEART LEFT VENTRICLE FUNCTION; HEART PACING; MIDDLE AGED; PATHOPHYSIOLOGY; SCINTISCANNING;

AGED; CARDIAC PACING, ARTIFICIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34250786208     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-1402.
2. Khand A, Gemmel I, Clark AL, Cleland JG. Is the prognosis of heart failure improving? J Am Coll Cardiol. 2000;36:2284-2286.
3. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
4. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026-2033.
5. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol. 2002;40:111-118.
6. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA. 2003;289:2685-2694.
7. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
8. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
9. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438-445.
10. Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy. Part 1. Issues before device implantation. J Am Coll Cardiol. 2005;46:2153-2167.
11. Bleeker GB, Kaandorp TA, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006;113:969-976.
12. Hummel JP, Lindner JR, Belcik JT, et al. Extent of myocardial viability predicts response to biventricular pacing in ischemic cardiomyopathy. Heart Rhythm. 2005;2:1211-1217.
13. 18F-FDG SPECT using acipimox for the assessment of myocardial viability. J Nucl Med. 2003;44:877-883.
14. Nuutila P, Knuuti MJ, Raitakari M, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol. 1994;267:E941-E946.
15. Beeres SL, Bax JJ, Dibbets P, et al. Effect of intramyocardial injection of autologous bone marrow-derived mononuclear cells on perfusion, function, and viability in patients with drug-refractory chronic ischemia. J Nucl Med. 2006;47:574-580.
16. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542.
17. 18F-fluorodeoxyglucose imaging to assess myocardial viability. Am J Cardiol. 2005;95:1223-1225.
18. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
19. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106-1107.
20. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. Br Med J (Clin Res Ed). 1986;292:653-655.
21. Alonso C, Leclercq C, Victor F, et al. Electrocardiographic predictive factors of long-term clinical improvement with multisite biventricular pacing in advanced heart failure. Am J Cardiol. 1999;84:1417-1421.
22. Diaz-Infante E, Mont L, Leal J, et al. Predictors of lack of response to resynchronization therapy. Am J Cardiol. 2005;95:1436-1440.
23. Woo GW, Petersen-Stejskal S, Johnson JW, Conti JB, Aranda JA Jr, Curtis AB. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J Interv Card Electrophysiol. 2005;12:107-113.
24. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884-888.
25. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation. 1998;98:II51-II56.
26. Knuuti MJ, Saraste M, Nuutila P, et al. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J. 1994;127:785-796.
27. Sciagra R, Leoncini M, Cannizzaro G, Marcucci G, Pupi A, Bisi G. Predicting revascularization outcome in patients with coronary artery disease and left ventricular dysfunction (data from the SEMINATOR study). Am J Cardiol. 2002;89:1369-1373.
28. Sciagra R, Giaccardi M, Porciani MC, et al. Myocardial perfusion imaging using gated SPECT in heart failure patients undergoing cardiac resynchronization therapy. J Nucl Med. 2004;45:164-168.
29. De Winter O, Van de Veire N, Van Heuverswijn F, Van Pottelberge G, Gillebert TC, De Sutter J. Relationship between QRS duration, left ventricular volumes and prevalence of nonviability in patients with coronary artery disease and severe left ventricular dysfunction. Eur J Heart Fail. 2006;8:275-277.
30. Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol. 1997;30:377-383.